Tag: multiparametric MRI

Italian culture is renowned for auto design. Arguably, many of the world’s most stunning cars were produced in the boot-shaped country by Ferrari, Maserati, Lamborghini and others. Their designers have been second to none, merging objective engineering and efficiency with subjective art. The autos they produced have often won not only historic races, but pure keep reading

When it comes to men’s health, you’re a responsible guy, right? You don’t overdo it on dietary fats, sugars, red meat and alcohol; you work out regularly; and you have an annual physical. And, your annual exam includes a PSA blood test if you’re over age 45 (age 40 if you have known risk factors). keep reading

Everyone with cancer worries at some level that it might come back after primary (first) treatment. There is the natural fear of the disease itself, but there’s also a mix of accompanying anxieties. A big one concerns the choice of secondary, or salvage, treatment if the primary treatment didn’t work. While these fears are more keep reading

We want to draw particular attention to a branch of AI called machine learning. When software is specifically “trained” to recognize imaging features, it can “… provide better standardization and consistency in identifying prostate lesions and enhance prostate carcinoma management.” One of the benefits is increased efficiency for busy radiologists who interpret MRI results and write reports. More importantly, however, is... keep reading

We are happy to report that an extensive body of literature on multiparametric MRI (mpMRI) of the prostate has mushroomed since the 2014 article cited in the original blog below. During the intervening years, more attention has been paid to mpMRI’s ability to distinguish between clinically insignificant prostate cancer (CISPCa) vs... keep reading

In the fall of 2015, I posted a blog on prostate cancer risk calculators, or nomograms, and how multiparametric MRI (mpMRI) improves risk assessment. I wrote, “A nomogram is a set of scales that can be used to calculate an unknown value, and when adapted for medicine, they act as a statistical modeling tool. The classic nomogram used to predict the chances that PCa has left the gland at the time of treatment is... keep reading

In September, 2018 we posted a blog on this promising news of the IsoPSA blood test for prostate cancer (PCa). Then, in October 2019, the FDA granted breakthrough device designation to the test, in order to work closely with the manufacturer to expedite approval. This move sprang from... keep reading

In recent years, there’s been a huge groundswell of Active Surveillance (AS) for low-risk prostate cancer (PCa) patients. In fact, it’s considered the preferred PCa management strategy for men with lower-risk disease. There are two primary factors at play: 1) patient resistance to undergoing definitive whole gland treatments that can impair urinary and sexual function, keep reading

When it comes to spending money, you have choices. According to wealthfit.com, “Whether you spend 10 seconds or 10 days weighing a decision, each one comes with strings attached. With each option you choose, you’re saying ‘no’ to a different option. The value of what you do not select is called your opportunity cost. You keep reading

You’re breezing along the railroad track of life. Like the steel wheels on a train, your choices in life have almost totally reduced friction and enhanced your midlife journey. Before you arrive at the next station, you’re at the peak of your career and in overall great health. Suddenly, where the steel meets the tracks, keep reading